TY - JOUR
T1 - Immune checkpoint inhibitors–related encephalitis in melanoma and non-melanoma cancer patients
T2 - a single center experience
AU - Taliansky, A.
AU - Furman, O.
AU - Gadot, M.
AU - Urban, D.
AU - Bar, J.
AU - Shapira-Frumer, R.
AU - Kaufman, B.
AU - Asher, N.
AU - Leibowitz-Amit, R.
AU - Itay, A.
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the incidence of n-irAE, focusing on immune-related encephalitis (IRE), in patients treated with ICI for multiple non-hematological malignancies in our institution. Methods: All patients with histologically verified cancer that received treatment with ICI at the Sheba Medical Center between January 2017 and August 2019 were surveyed. Medical records for each patient were reviewed and information regarding n-irAE was recorded. Results: In total, 1993 patients were included. Eleven cases of IRE were recorded, affecting 0.55% of patients overall, eight had non-melanoma cancer. Eight patients had made a full recovery. Conclusions: IRE is a n-irAE more frequent than previously reported, particularly in non-melanoma patients. The diagnostic criteria and optimal treatment needs to be determined. ICI re-challenge after IRE can be considered for selected patients.
AB - Background: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the incidence of n-irAE, focusing on immune-related encephalitis (IRE), in patients treated with ICI for multiple non-hematological malignancies in our institution. Methods: All patients with histologically verified cancer that received treatment with ICI at the Sheba Medical Center between January 2017 and August 2019 were surveyed. Medical records for each patient were reviewed and information regarding n-irAE was recorded. Results: In total, 1993 patients were included. Eleven cases of IRE were recorded, affecting 0.55% of patients overall, eight had non-melanoma cancer. Eight patients had made a full recovery. Conclusions: IRE is a n-irAE more frequent than previously reported, particularly in non-melanoma patients. The diagnostic criteria and optimal treatment needs to be determined. ICI re-challenge after IRE can be considered for selected patients.
KW - Autoimmune encephalitis
KW - Immune checkpoint inhibitor adverse event
KW - Immune checkpoint inhibitor–related encephalitis
UR - http://www.scopus.com/inward/record.url?scp=85107728667&partnerID=8YFLogxK
U2 - 10.1007/s00520-021-06331-5
DO - 10.1007/s00520-021-06331-5
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34120259
AN - SCOPUS:85107728667
SN - 0941-4355
VL - 29
SP - 7563
EP - 7568
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 12
ER -